NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab.

ABSTRACT:

Background

Early identification of cardiac dysfunction by non-invasive imaging in HER2-positive breast cancer patients treated with trastuzumab is challenging. In particular multigated acquisition (MUGA) scan, which is most widely used, is unable to detect subclinical cardiac changes. The use of N-terminal pro-brain natriuretic peptide (NT-proBNP), a serum biomarker of myocardial stress, might improve timely diagnosis.

Methods

This prospective, single-center, cohort study included patients with HER2-positive breast cancer who started trastuzumab therapy. Echocardiography was scheduled at regular intervals every 3 months during one year follow-up for cardiac function monitoring. For research purposes, NT-proBNP was determined at the same time points. Trastuzumab-induced cardi

SUBMITTER: Bouwer NI 

PROVIDER: S-EPMC7048136 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature